For the first time, Medicare isn’t just accepting whatever prices the drug corporations set for expensive and widely used drugs in Part D like Xareto and Eliquis–instead, the agency, newly empowered under the new Medicare negotiations law, will propose lower prices for ten of the most expensive drugs in Medicare Part D to kick off the negotiations process.
Statement from Margarida Jorge, head of Lower Drug Prices Now in response to implementation of the latest provision of the 2022 Inflation Reduction Act’s Medicare reforms to lower drug prices for millions of seniors and people with disabilities:
Statement from Margarida Jorge, head of Lower Drug Prices Now in response to news that prescription drug corporations will raise prices on over 500 prescription drugs in the first half of 2024.
Statement from Margarida Jorge, head of Lower Drug Prices Now in response to the U.S. District Court for the Southern District of Ohio rejecting the Chamber of Commerce’s request for an injunction to stop implementation of Medicare negotiations to lower drug prices.
The Inflation Reduction Act continues to deliver on lowering health care costs for millions of Americans and reining in corporate greed with historic reforms that will help patients, rein in profits and save taxpayers billions.
This is nothing but a political stunt motivated by the same shameless greed that we’re used to seeing from drug corporations that have made decades of inflated profits at the expense of patients’ health and taxpayers’ hard-earned money.
Statement from Margarida Jorge, head of Lower Drug Prices Now – the leading campaign fighting to lower prescription drug prices – in response to Merck’s lawsuit against Medicare prescription drug negotiation:
This is nothing but a political stunt motivated by the same shameless greed that we’re used to seeing from drug corporations that have made decades of inflated profits at the expense of patients’
…
